Hanmi Pharma (128940 KS Oct 28, 2025) - Hunting the KOSPI Obesity Leader
Hanmi unveiled phase 3 trial results for next-gen obesity drug efpeglenatide Fewer side effects, better affordability; a practical obesity...
493 Views
APAC Healthcare Weekly (July 26) – Hengrui, BeOne, Takeda, Nippon Shinyaku, Samsung Bio, Celltrion
Hengrui’s camrelizumab got indication expansion approval for cervical cancer. BeOne announced $300M expansion plan for US facility. Samsung...
132 Views
APAC Healthcare Weekly (July 12) – Sino Bio, Hansoh Pharma, Wuxi Bio, Astellas, Otsuka, Celltrion
Sino Bio stuck outlicensing deal with AstraZeneca. Hansoh’s ADC drug candidate met primary endpoint in Phase 3 trial. China will review Astellas’...
133 Views
[2H26 Outlook] Pharma/BiotechCatalysts for a biotech rebound
Biotech stocks performed well early this year, driven by optimism surrounding the government's KOSDAQ 3,000 target and supportive fund flows...
119 Views
APAC Healthcare Weekly (June 7) – CSPC Pharma, Innovent, Shionogi, Hanmi Pharm, SK Bioscience, Lupin
Innovent submitted NDA for oncology drug. Shionogi got FDA approval for Xocova. Hanmi Pharm signed $1.2B outlicensing deal with Lilly. SK...
167 Views